Minneapolis, MN, July 11, 2017 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company
developing a proprietary platform designed to address an unmet technology need within the $4+ billion electrophysiology (EP)
marketplace, today announced that the Company has engaged Health Research International (HRI) to compile essential market data and
help perform strategic planning for its PURE EP(TM) platform technology. Project goals include understanding and presenting the
clinical relevance of BioSig’s technology, pricing strategies, and envisioning optimal applications of BioSig’s platform technology
beyond EP. In addition to benefitting from HRI’s acknowledged research expertise, the Company will gain access to HRI’s extensive
network in the medical field. As such, this collaboration will provide further meaningful input regarding new products,
technologies, and clinical applications, as the Company moves closer to the commercialization of the PURE EP System.
Health Research International is a “boutique” medical market research and business development firm with more than 30 years of
experience addressing the needs of companies ranging from small start-ups to the largest medical device companies in the world.
HRI’s custom consulting services include comprehensive market analyses and forecasts, focus groups, end user surveys and
interviews, regulatory and reimbursement analyses, competitive analyses of products and companies, pricing sensitivity studies and
econometric market modeling.
According to Suzanne Ratzloff, President of Health Research International, “Our surveys and interviews have documented the
challenges electrophysiologists face performing intricate catheter ablations for complex arrhythmias, and they suggest that
BioSig’s PURE EP System could represent a solution, both facilitating and expediting those procedures. Moreover, we believe
the clarity afforded by BioSig’s intelligent signal acquisition technology could prove invaluable and even enabling for the
development of other clinically meaningful technologies, especially within the emerging field of bioelectronics. As such, we are
delighted that BioSig is involving us in its investigation and documentation of these opportunities.”
“We are very excited to work with Suzanne Ratzloff and her team at Health Research International during this pivotal point in
our product development,” stated Ken Londoner, Chairman and CEO of BioSig Technologies. “I have known Suzanne for many years and
know the impact that this group has had on many established and emerging technologies. HRI has been instrumental in supporting many
companies’ marketing efforts ensuring successful investor presentations and product launches. We are very much looking forward to
this collaboration for our PURE EP System launch and for our future technologies.”
About BioSig Technologies
BioSig Technologies is a medical device company developing a proprietary technology platform designed to improve the $4+ billion
electrophysiology (EP) marketplace (www.biosigtech.com). Led by a proven management team and a veteran, independent Board of
Directors, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP(TM) System. The technology has
been developed to address an unmet need in a large and growing market.
The PURE EP System is a novel cardiac signal acquisition and display system which is engineered to assist electrophysiologists
in clinical decision making during procedures to diagnose and treat patients with abnormal heart rates and rhythms. BioSig’s main
goal is to deliver technology to improve upon catheter ablation treatments for prevalent and deadly arrhythmias. BioSig has
partnered with Minnetronix on technology development and is working toward FDA 510(k) clearance and CE Mark for the PURE EP
System.
Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words.
Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various
known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified
and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such
risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our
product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining
financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key
executives or scientists; and (v) difficulties in securing regulatory approval to market our product candidates.. More detailed
information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in
the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its
Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web
site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a
result of new information, future events or otherwise.
Investor Relations: Lora Mikolaitis BioSig Technologies, Inc. lmikolaitis@biosigtech.com 310.948.7200
